Diagnostics & Research Stocks
34 US-listed diagnostics & research companies above our tradable floor ($5 and $1 million a day), largest first, with each one's stage, price and valuation after the close.
34
companies
27 (79%)
in a Stage 2 uptrend
+22.0%
3-month return, weighted by size
1 · 4 · 2
in Stage 1 · 3 · 4
Only the Stage 2 ones →Filter them in the screener →All Health Care stocks →Industry rotation →
Every diagnostics & research stock we cover
| Stock | Stage | Close | Day | 3 months | From high | RS | P/E | Yield | Market cap |
|---|---|---|---|---|---|---|---|---|---|
| TMOThermo Fisher Scientific | Stage 2, wk 11 | $697.00 | -1.7% | +21.5% | -1.7% | 73 | 35.7 | 0.27% | $258B |
| DHRDanaher | Stage 2, wk 8 | $232.23 | -2.0% | +17.8% | -3.5% | 61 | 38.1 | 0.68% | $163B |
| NTRANatera | Stage 2, wk 21 | $414.30 | -5.0% | +53.2% | -5.0% | 96 | — | — | $59.7B |
| AAgilent Technologies | Stage 2, wk 14 | $174.87 | -3.5% | +25.3% | -3.6% | 71 | 34.3 | 0.57% | $49.3B |
| WATWaters | Stage 2, wk 18 | $462.72 | -3.6% | +23.5% | -3.6% | 79 | 115.3 | — | $45.4B |
| IQVIQVIA Holdings | Stage 2, wk 13 | $267.33 | -2.8% | +14.6% | -4.3% | 71 | 34.6 | — | $44.1B |
| IDXXIDEXX Laboratories | Stage 4, wk 8 | $551.21 | -4.3% | -2.9% | -28.1% | 45 | 39.8 | — | $43.4B |
| ILMNIllumina | Stage 2, wk 25 | $235.99 | -18.6% | +19.1% | -19.6% | 97 | 50.3 | — | $35.7B |
| MTDMettler-Toledo International | Stage 2, wk 10 | $1,674.81 | -2.5% | +15.9% | -2.5% | 69 | 38.0 | — | $33.6B |
| LHLabcorp Holdings | Stage 2, wk 15 | $361.39 | -1.8% | +17.8% | -1.8% | 84 | 27.3 | 0.89% | $29.3B |
| DGXQuest Diagnostics | Stage 2, wk 18 | $251.82 | -0.4% | +9.0% | -0.4% | 84 | 25.9 | 1.44% | $27.8B |
| GHGuardant Health | Stage 2, wk 23 | $178.80 | -3.5% | +12.6% | -4.5% | 97 | — | — | $24.0B |
| MEDPMedpace Holdings | Stage 2, wk 12 | $652.01 | -3.8% | +13.7% | -5.9% | 62 | 36.3 | — | $18.2B |
| RVTYRevvity | Stage 2, wk 19 | $157.00 | -5.3% | +36.3% | -5.3% | 90 | 75.3 | 0.18% | $17.5B |
| CRLCharles River Laboratories International | Stage 2, wk 17 | $359.41 | -4.4% | +55.7% | -4.4% | 95 | — | — | $17.3B |
| ICLRICON | Stage 2, wk 14 | $211.36 | -1.9% | +33.4% | -1.9% | 74 | 195.2 | — | $15.8B |
| QGENQiagen | Stage 2, wk 7 | $50.22 | -0.2% | +18.6% | -9.0% | 59 | 25.5 | 0.70% | $10.4B |
| GRALGRAIL | Stage 2, wk 8 | $143.43 | -9.7% | +104.1% | -9.7% | 90 | — | — | $6.4B |
| RDNTRadNet | Stage 2, wk 10 | $73.49 | -0.2% | +10.0% | -13.0% | 48 | — | — | $5.8B |
| BLLNBillionToOne | Stage 3, wk 9 | $113.32 | -1.3% | -17.5% | — | — | 167.7 | — | $5.3B |
| SHCSotera Health | Stage 3, wk 1 | $18.15 | -2.9% | +0.9% | -7.3% | 61 | 31.8 | — | $5.2B |
| CDNACareDx | Stage 2, wk 25 | $87.41 | +22.2% | +82.7% | 0.0% | 99 | 33.3 | — | $4.6B |
| ADPTAdaptive Biotechnologies | Stage 2, wk 18 | $26.64 | -5.4% | +15.3% | -10.7% | 88 | — | — | $4.3B |
| VCYTVeracyte | Stage 3, wk 10 | $50.01 | -4.1% | +11.5% | -17.3% | 82 | 32.9 | — | $4.0B |
| NEONeoGenomics | Stage 2, wk 17 | $17.38 | -3.1% | +9.7% | -12.7% | 91 | — | — | $2.2B |
| WGSGeneDx Holdings | Stage 3, wk 1 | $69.06 | -2.8% | +1.8% | -58.8% | 25 | — | — | $2.1B |
| PSNLPersonalis | Stage 2, wk 18 | $15.82 | -0.7% | +19.8% | -13.9% | 90 | — | — | $1.7B |
| FRNMFreenome | Stage 2, wk 9 | $12.48 | -3.0% | +13.4% | -27.1% | 66 | — | — | $1.3B |
| CSTLCastle Biosciences | Stage 2, wk 7 | $37.16 | -3.5% | +22.3% | -13.7% | 88 | — | — | $1.1B |
| MYGNMyriad Genetics | Stage 1, wk 2 | $6.35 | -4.8% | +110.3% | -22.4% | 39 | — | — | $607M |
| FLGTFulgent Genetics | Stage 2, wk 5 | $20.62 | -4.9% | +17.1% | -33.2% | 47 | — | — | $567M |
| BDSXBiodesix | Stage 2, wk 19 | $23.26 | -5.9% | +5.6% | -24.0% | 98 | — | — | $245M |
| XGNExagen | Stage 2, wk 11 | $8.59 | -1.3% | +83.5% | -27.4% | 35 | — | — | $208M |
| PRPOPrecipio | Stage 4, wk 1 | $18.10 | -6.5% | -18.2% | -44.1% | 45 | — | — | $32.4M |
Diagnostics & Research Stocks: quick answers
How many diagnostics & research stocks are in an uptrend?
As of Oct 30, 2026, 27 of the 34 US-listed diagnostics & research stocks we cover are in Stage 2, the uptrend phase, including Thermo Fisher Scientific (TMO), Danaher (DHR), Natera (NTRA), Agilent Technologies (A) and Waters (WAT).
What is the largest diagnostics & research stock?
Thermo Fisher Scientific (TMO), with a market value of $258B. It closed at $697.00 on Oct 30, 2026, in Stage 2.
Which diagnostics & research stocks are near their 52-week high?
As of Oct 30, 2026, 6 are within 5% of a 52-week high: Thermo Fisher Scientific (TMO), Danaher (DHR), Natera (NTRA), Agilent Technologies (A), Waters (WAT) and IQVIA Holdings (IQV).
End-of-day data for common stocks and ADRs on the NYSE, Nasdaq and NYSE American, computed after each US close and dated to the trading session.